Current Technology's ETG Mark I Receives CE Medical Mark
VANCOUVER, British Columbia, Feb. 23 /PRNewswire-FirstCall/ -- Current Technology Corporation (BULLETIN BOARD: CRTCF.OB) , developer of ETG (ElectroTrichoGenesis), a patented electrotherapeutic device that provides a clinically proven medical treatment for hair loss, announced today that it has received the CE Medical Mark for its ETG Mark I device.
During the last quarter of 2004 KEMA Quality B.V., Arnhem, The Netherlands, conducted audits and examinations in accordance with the applied conformity assessment procedures and has determined that the quality system maintained by Current Technology and its ETG Mark 1 (ElectroTrichoGenesis) electric pulse stimulator for the treatment of hair loss comply with the requirements of EC-directive 93/42/EEC and amendments thereto. Therefore, KEMA has issued certificate number 2076469CE01 valid until March 1, 2008 authorizing Current Technology to affix the "CE Marking of Conformity" to its ETG Mark 1 medical devices.
"The CE Mark is the gold standard for medical devices in virtually every country in the world outside of the United States," states COO Anthony Harrison. "Our ability to affix the CE Mark to our ETG Mark 1 devices confirms Current Technology's ongoing compliance with a rigorous quality assurance and quality control program."
"Issuance of the CE Mark has particular significance in Asia," states Robert Kramer, CEO of Current Technology. "We are now in a position to commence the final steps required to deliver ETG devices to Malaysia, the Hong Kong Special Administrative Region and Taiwan.
This milestone further serves to underscore the importance of ongoing negotiations in Australasia. We are presently negotiating distribution agreements for Japan, the Philippines, Indonesia, Thailand and Australia. This dynamic part of the world holds significant promise for us in 2005."
About ETG and Current Technology Corporation
Current Technology Corporation is the developer of ETG (ElectroTrichoGenesis) a patented electrotherapeutic device that provides a clinically proven medical treatment for hair loss. ETG treatment centers are presently available in eleven countries around the world. ETG has been shown to be useful in preventing or reducing hair loss in women undergoing CMF chemotherapy for breast cancer.Current Technology Corporation
CONTACT: Robert Kramer of Current Technology Corporation, +800-661-4247,or +1-604-684-2727, or email@example.com; or investors, Richard Hannon ofPolestar Communications, +866-858-4100; or media, Rob Wyse of Media FirstPublic Relations, Inc., +1-216-577-1184, or firstname.lastname@example.org, both forCurrent Technology Corporation
Web site: http://www.etgtreatment.com/